Vanda Pharmaceuticals Inc.
VNDA
$3.92
-$0.06-1.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.37% | 3.18% | -9.91% | -23.63% | -30.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.37% | 3.18% | -9.91% | -23.63% | -30.81% |
| Cost of Revenue | -15.35% | -23.53% | -30.67% | -39.05% | -42.45% |
| Gross Profit | 15.73% | 5.41% | -8.03% | -22.16% | -29.64% |
| SG&A Expenses | 55.72% | 29.70% | 7.12% | -7.24% | -18.88% |
| Depreciation & Amortization | 87.91% | 247.99% | 327.04% | 236.83% | 145.98% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.02% | 15.90% | 7.66% | -6.20% | -15.74% |
| Operating Income | -187.61% | -191.43% | -16,264.63% | -435.64% | -257.42% |
| Income Before Tax | -1,343.68% | -461.59% | -202.68% | -151.57% | -115.80% |
| Income Tax Expenses | -1,198.17% | -204.99% | -129.04% | -112.47% | -87.72% |
| Earnings from Continuing Operations | -805.05% | -853.29% | -239.24% | -173.32% | -130.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -805.05% | -853.29% | -239.24% | -173.32% | -130.64% |
| EBIT | -187.61% | -191.43% | -16,264.63% | -435.64% | -257.42% |
| EBITDA | -213.00% | -197.28% | -1,419.25% | -316.00% | -210.29% |
| EPS Basic | -794.92% | -835.29% | -236.47% | -171.91% | -130.05% |
| Normalized Basic EPS | -388.19% | -1,131.03% | -280.42% | -200.94% | -158.09% |
| EPS Diluted | -723.79% | -1,028.13% | -242.75% | -176.46% | -133.19% |
| Normalized Diluted EPS | -388.19% | -1,112.45% | -281.66% | -201.63% | -158.51% |
| Average Basic Shares Outstanding | 1.33% | 1.32% | 1.37% | 1.47% | 1.55% |
| Average Diluted Shares Outstanding | 1.26% | 1.08% | 0.90% | 0.88% | 0.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |